Palbociclib (PD-0332991) HCl Licensed by Pfizer

Catalog No.S1116

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Palbociclib (PD-0332991) HCl Chemical Structure

Palbociclib (PD-0332991) HCl Chemical Structure
Molecular Weight: 483.99

Validation & Quality Control

Customer Product Validation(6)

Quality Control & MSDS

Related Compound Libraries

CDK Inhibitors with Unique Features

  • Pan CDK Inhibitor

    BAY 1000394 Pan-CDK1/2/3/4/7/9 inhibitor, IC50=5-25 nM.

  • Most Potent CDK Inhibitor

    LY2835219 CDK4, IC50=2 nM; CDK6, IC50=10 nM.

  • CDK Inhibitor in Clinical Trial

    Dinaciclib (SCH727965) Phase III for Chronic Lymphocytic Leukemia (CLL).

  • Newest CDK Inhibitor

    NU6027 Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Product Information

  • Compare CDK Inhibitors
    Compare CDK Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Targets CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
CDK2/CyclinE2 [1]
(Cell-free assay)

 View  More

IC50 9 nM 11 nM 15 nM >10 μM
In vitro PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MOLM13MnnzT4lv[XOnIFHzd4F6NVniUJViOjRiaB?=NUnkRW46UW6qaXLpeIlwdiCxZjDDSGs1KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhWmJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxOiEQvF2=MVKyOFY1OTFyMx?=
COLO205NIjJ[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFX1O4U4OiCqNIi4dpZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEO2JO69VQ>?MXOyOFY1OTFyMx?=
U937NFnjPI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTPO|IhcA>?M3nDUGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5zNDFOwG0>NGqxd|UzPDZ2MUGwNy=>
MOLM13NXPCRmpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXe3NkBpMWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTF2xN{Bk\WyuczDoZZJjd3KrbnegSmxVOyCLVFSgcZV1[W62IHHzd4V{e2WmIHHzJIlv[2:{cH;yZZRqd25ib3[gX|NJZXSqeX3p[Ilv\SCrboTvJGRPSSC5aYToJGlEPTBib3[gNE4xQTZizszNMWqyOFY1OTFyMx?=
MOLM13NVTnUVRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvmO|IhcA>?NF\YN3dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJNwemGoZX7pZk1z\XOrc4ThcpQhcHWvYX6gUW9NVTF|IHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ49zeG:{YYTpc44hd2ZiW{PIYZRpgW2rZHnu[UBqdnSxIFTORUB4cXSqIFnDOVAhd2ZiMD6wPVYh|ryPMWiyOFY1OTFyMx?=
MDA-MB-435MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvaNlQhcA>?MVPJR|UxRTBwMU[g{txOMnPLNVU5ODF6M{G=
K562NGrZT3hEgXSxdH;4bYMhSXO|YYm=M2XmPVk3KGh?M1:zU2ROW09?M4LjSGlEPTB;MjFOwG0>MXeyOFQyPzV4Nh?=
DU145Mnf1R5l1d3SxeHnjJGF{e2G7NVfEWmJ4QTZiaB?=MlXuSG1UVw>?NX;UT4ZQUUN3ME23MlUh|ryPMkf2NlQ1OTd3Nk[=
MDA-MB-231NGnpXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\rNUDPxE1?NWjhWnpFOjRiaB?=M4jV[WROW09?NHL5[|JE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U>NHK5SXczPDRzN{W2Oi=>
MCF7NVnZbVJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWOyUnVxOSEQvF2=M3nCNFI1KGh?NIPtc5dFVVORMkLUR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPlMVeyOFQyPzV4Nh?=
MCF7MkX0T4lv[XOnIFHzd4F6M4DWWVUh|ryPMnjaNlQhcA>?MkDpSG1UVw>?MXzJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFPET|Qw[3mlbHnuSFEh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBz\XSrbn;icIF{fG:vYTDwbI9{eGixconsZZRqd25iYYSgV4VzPzhyMWiyOFQyPzV4Nh?=
MDA-MB-231NYf4OXozU2mwYYPlJGF{e2G7Ml[xOUDPxE1?MlHxNlQhcA>?M1;3b2ROW09?NVXZT4FkUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=>NYTNWGNWOjR2MUe1OlY>
MDA-MB-231MVrGeY5kfGmxbjDBd5NigQ>?MXWxMVExKM7:TR?=NHjD[XAzPCCqNYLmO3Q5TE2VTx?=MXXkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V?NYPZbmg1OjR2MUe1OlY>
MCF7MWnGeY5kfGmxbjDBd5NigQ>?MoTRNU0yOCEQvF2=MYKyOEBpMVzEUXNQM4r5NoRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?=NU\qb2tXOjR2MUe1OlY>
MDA-MB-231Mk\vSpVv[3Srb36gRZN{[Xl?NIfTemYxNjVvMTFOwG0>NXW4e|c4PDhiaB?=M3PpVmROW09?NEnuVVdp[XNibn:gR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JJN2[i2JMTDwbIF{\Q>?NVT2cJc{OjR2MUe1OlY>
MCF7NYXVcnF7TnWwY4Tpc44hSXO|YYm=M1i3e|AvPS1zIN88US=>M1rueFQ5KGh?M2S2cGROW09?Mn3ibIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U>M{nE[FI1PDF5NU[2
697MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzUN3lKSzVyPUG0PE4{QCCwTR?=NWnDeZpEW0GQR1XS
P12-ICHIKAWAMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmG1TWM2OD17Nj6wOEBvVQ>?NXjMdJR6W0GQR1XS
NB69NFTrZ|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYn3R5h{UUN3ME2xOlEvQCCwTR?=MUXTRW5ITVJ?
EoL-1MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTF6Nz6yOkBvVQ>?M1\HbnNCVkeHUh?=
BHT-101M4LoRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTF7OD6yOUBvVQ>?MXHTRW5ITVJ?
SK-NEP-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnG5TWM2OD1{MkCuNFIhdk1?MWrTRW5ITVJ?
MHH-NB-11MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLBTWM2OD1{MkCuNVkhdk1?NH33bmlUSU6JRWK=
AsPC-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIGweXRKSzVyPUK1Nk42OyCwTR?=MnTxV2FPT0WU
ES1NEG2VFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTJ3Nj6yOUBvVQ>?NWWwbVJbW0GQR1XS
LAMA-84NYfmOno5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLDXW1KSzVyPUK1PE4yQSCwTR?=MmDrV2FPT0WU
MOLT-16M3nYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkHWTWM2OD1{NUiuOFkhdk1?MnPYV2FPT0WU
ES7MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3j3WGlEPTB;MkezMlA6KG6PMXXTRW5ITVJ?
KY821MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHL1NoJKSzVyPUOxOE4yKG6PMXfTRW5ITVJ?
RT-112MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17JS2lEPTB;M{KxMlA2KG6PMXzTRW5ITVJ?
HL-60M2DDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPxWFJKSzVyPUO0NE43PiCwTR?=NFj3[GRUSU6JRWK=
MOLT-4MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrUbJZKSzVyPUO0OU4yOyCwTR?=NHW1S5pUSU6JRWK=
KARPAS-45MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFG2SZZKSzVyPUO3Ok4yPiCwTR?=MmnDV2FPT0WU
SK-N-ASM4q2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfac5UxUUN3ME2zPFcvQDNibl2=MUnTRW5ITVJ?
CTB-1M{LEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTZTWM2OD12MEWuNFIhdk1?NYLieIszW0GQR1XS
NKM-1MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTRzMT64PUBvVQ>?NEntTHhUSU6JRWK=
HTC-C3NWnSPGJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlfyTWM2OD12M{KuPVUhdk1?NGPMPXZUSU6JRWK=
BE-13MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2KySmlEPTB;NES0MlI4KG6PMWPTRW5ITVJ?
KOSC-2NVTE[pZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXP2[4ZkUUN3ME20OlYvQSCwTR?=NF7v[npUSU6JRWK=
NB14MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4n0WGlEPTB;NEizMlU5KG6PNG\PenFUSU6JRWK=
CAL-27M3TtWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1ewb2lEPTB;NEm0MlU6KG6PMojVV2FPT0WU
H9M2TWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELaTGdKSzVyPUS5OU41OyCwTR?=M3H5S3NCVkeHUh?=
RS4-11MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVizd2FoUUN3ME21NFQvPzNibl2=MYDTRW5ITVJ?
PA-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTVyOT64OkBvVQ>?M{LkcnNCVkeHUh?=
MV-4-11NFnTc|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTVzMz64OUBvVQ>?MoWyV2FPT0WU
OS-RC-2M2P6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTV{MT62NkBvVQ>?MXnTRW5ITVJ?
RPMI-8226MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTV{Nj64OkBvVQ>?NWPKN5hqW0GQR1XS
HGC-27NXuxSoJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTV4ND65PUBvVQ>?MV\TRW5ITVJ?
CHP-212MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoH6TWM2OD13OUOuOVkhdk1?NGflXIxUSU6JRWK=
NB10M32xRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTV7OT6xPEBvVQ>?MnHEV2FPT0WU
HHMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17XSWlEPTB;NUm5MlQ{KG6PNVPrbHhTW0GQR1XS
EW-16M1z1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PlXWlEPTB;NkCzMlUzKG6PMnHUV2FPT0WU
ES8NGPNXndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIr6eY1KSzVyPU[wOU4zOSCwTR?=MnvqV2FPT0WU
HAL-01NY[5Z3E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHsN4NKSzVyPU[wOU43PyCwTR?=MWXTRW5ITVJ?
A204NFrYNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjCSVZKSzVyPU[zN{46OSCwTR?=NYPXfJM{W0GQR1XS
MHH-PREB-1NX7NOJFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELkW|hKSzVyPU[zOk46QSCwTR?=NWOyUYRuW0GQR1XS
EM-2NHzXTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTZ3MD62OEBvVQ>?M3SzXXNCVkeHUh?=
BV-173NYnjUJU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTZ3Mj60PEBvVQ>?NGi5bpRUSU6JRWK=
ONS-76MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDmTWM2OD14N{euPFIhdk1?MUPTRW5ITVJ?
KM-H2NY\zWGUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnMUWh7UUN3ME22PVUvPTRibl2=NF:zPXBUSU6JRWK=
D-263MGMmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUTPV3A2UUN3ME23NVcvOTJibl2=NYq2T3VOW0GQR1XS
ES3Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTd{OD65N{BvVQ>?NGH2VnVUSU6JRWK=
VA-ES-BJNEi1Zm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7DTWM2OD15M{KuNlchdk1?M161UHNCVkeHUh?=
NBsusSRNV7YOlZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TCb2lEPTB;N{SyMlk6KG6PMmSwV2FPT0WU
NCI-H520MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MorCTWM2OD15NE[uOVIhdk1?MkWzV2FPT0WU
ES5MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXG4SGtVUUN3ME23OVIvQCCwTR?=MnKyV2FPT0WU
T-24MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTsbnZuUUN3ME23O|gvPzFibl2=M3vERXNCVkeHUh?=
SW962NHfBNZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULGV257UUN3ME24NFgvPjNibl2=NVnBV4cyW0GQR1XS
EW-3NFLBdpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPYTWM2OD16MEiuO|Yhdk1?M37XW3NCVkeHUh?=
RXF393MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7KdIxsUUN3ME24NVIvPzlibl2=M3Kzb3NCVkeHUh?=
U251NIHJdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRThzMz64PEBvVQ>?MX7TRW5ITVJ?
CAMA-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPVN|dZUUN3ME24N|MvQTRibl2=M4nlVnNCVkeHUh?=
JVM-3MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTh3MT63PEBvVQ>?NXO5[ZU2W0GQR1XS
COLO-800Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1OwdmlEPTB;OEm3Mlc5KG6PM1XiXXNCVkeHUh?=
OVCAR-5NEToW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjCO5ZmUUN3ME25NFAvOSCwTR?=NFu0eW5USU6JRWK=
LB1047-RCCNFrteG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\sTWM2OD17MkeuOVYhdk1?MmjhV2FPT0WU
SW954NITNVHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTl{OT60NUBvVQ>?NGXmb5RUSU6JRWK=
J-RT3-T3-5MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zUb2lEPTB;OUO2MlA3KG6PNFr6[VNUSU6JRWK=
MewoMmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDhTWM2OD17M{[uOkBvVQ>?Mo\UV2FPT0WU
NCI-H1770NGqye3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HocGlEPTB;OUSwMlU2KG6PMWjTRW5ITVJ?
HO-1-N-1NInT[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vnTmlEPTB;OU[yMlgyKG6PMn:3V2FPT0WU
HSC-3NWPLeFJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU[4W252UUN3ME25OlYvPDhibl2=MnOxV2FPT0WU
TYK-nuMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDoeoc2UUN3ME25PVgvOjVibl2=Mo[zV2FPT0WU
KYSE-150M3\EbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTFwMECwO|Yh|ryPM4SyfXNCVkeHUh?=
SN12CNEDEUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2HaUWlEPTB;MT6wNFg4PSEQvF2=MVrTRW5ITVJ?
MOLT-13NYK3TYJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTFwMEG0NlEh|ryPMVPTRW5ITVJ?
TE-11NG\5cXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlO3TWM2OD1zLkC0PFEzKM7:TR?=NGfTb2RUSU6JRWK=
DBMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrWe5pKSzVyPUGuNFczPzNizszNM33jenNCVkeHUh?=
CAL-39MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4L0bWlEPTB;MT6wO|UzOiEQvF2=Mkj0V2FPT0WU
A3-KAWNF\FUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTFwMEi0NFgh|ryPMWTTRW5ITVJ?
CHP-134MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfZVlBPUUN3ME2xMlEyQDB5IN88US=>MnnmV2FPT0WU
TGWMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\uSpNKSzVyPUGuNVI{QTVizszNM2W2b3NCVkeHUh?=
QIMR-WILNVzmVJNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDzTWM2OD1zLkGzNVM1KM7:TR?=MkDGV2FPT0WU
NCI-SNU-1MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHme|JiUUN3ME2xMlE3OzV2IN88US=>MnvaV2FPT0WU
CGTH-W-1MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTFwMUexPFYh|ryPMnzFV2FPT0WU
MHH-ES-1MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTFwMUe5PFYh|ryPMWTTRW5ITVJ?
LB2241-RCCNV64VHZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jMfmlEPTB;MT6xPFYzKM7:TR?=NGWyR|lUSU6JRWK=
ML-2NX32V2hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\3e3A{UUN3ME2xMlIxPzN2IN88US=>NX\DTm84W0GQR1XS
COR-L23NIDlZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfaXopqUUN3ME2xMlIzQTN|IN88US=>MUHTRW5ITVJ?
BFTC-905MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDmTWM2OD1zLkK0NlY4KM7:TR?=MkDKV2FPT0WU
Hs-578-TNXjZXJduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGG4VJBKSzVyPUGuNlU5OTdizszNMWDTRW5ITVJ?
KG-1M{n4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTFwMk[2PFYh|ryPMYTTRW5ITVJ?
HELNFTJfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnMZYlKSzVyPUGuNlk{OzhizszNMYrTRW5ITVJ?
A549M{LFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LrU2lEPTB;MT6yPVM6QSEQvF2=MkGzV2FPT0WU
COLO-741MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTFwM{KwPFkh|ryPNFHYRnhUSU6JRWK=
PC-3MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTHS3hGUUN3ME2xMlM2OjJzIN88US=>NV7C[4RvW0GQR1XS
HOSM1nZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLDc5dKSzVyPUGuN|UzQTZizszNMYLTRW5ITVJ?
HT-1080NV:2TXJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTFwM{e1NVkh|ryPMUfTRW5ITVJ?
TE-8M1jNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUP1T4ViUUN3ME2xMlQyPzd2IN88US=>MYnTRW5ITVJ?
BHYM4na[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTFwNE[5NlMh|ryPMkfjV2FPT0WU
BB65-RCCNFn2bpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPNPZpKSzVyPUGuOVA2OjhizszNMVvTRW5ITVJ?
HNMoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvPWmVqUUN3ME2xMlU1ODdzIN88US=>NGTERWJUSU6JRWK=
NCI-H441M2DrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTFwNUS5NFch|ryPMoi1V2FPT0WU
RPMI-8866NHridlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTFwNUi1NFch|ryPMYrTRW5ITVJ?
CAL-62MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjZVnlKSzVyPUGuOlA5PjJizszNMUjTRW5ITVJ?
MG-63MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{f4PGlEPTB;MT62NVgyOyEQvF2=M{jGPXNCVkeHUh?=
SK-LU-1M1;2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\ROpJKSzVyPUGuOlIyPTJizszNMUPTRW5ITVJ?
BCPAPMmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvwNmlKSzVyPUGuOlY1PTdizszNNXPKS2ppW0GQR1XS
22RV1M1O5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUP2TId1UUN3ME2xMlY4QDR|IN88US=>MYDTRW5ITVJ?
T47DNES2dmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLUTWM2OD1zLk[4NFYyKM7:TR?=MXfTRW5ITVJ?
MSTO-211HMln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTFwNkm2NFMh|ryPM2TkV3NCVkeHUh?=
DELM4jSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTFwN{CyO|Mh|ryPMnPPV2FPT0WU
H4NFLQOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTFwN{OyNVIh|ryPNInqdVNUSU6JRWK=
CAL-51MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTuTWM2OD1zLke0PFU2KM7:TR?=M4rkTXNCVkeHUh?=
ABC-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33QZmlEPTB;MT63PFU5OiEQvF2=NIHWbFRUSU6JRWK=
MZ2-MELNUPmW5lCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn33TWM2OD1zLke5OVQzKM7:TR?=NUfOT2s5W0GQR1XS
YKG-1NUKw[oxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjYTWM2OD1zLkixNFYyKM7:TR?=NVSzdVNPW0GQR1XS
KM12MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjBRXM4UUN3ME2xMlgyPjB{IN88US=>MmjDV2FPT0WU
L-363M1XvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vwbmlEPTB;MT64O|QyOiEQvF2=MofrV2FPT0WU
KU812M4ezPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXNTWM2OD1zLki5NlgzKM7:TR?=MmDjV2FPT0WU
LOXIMVIMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nuO2lEPTB;MT65NVIzQCEQvF2=NILWS2JUSU6JRWK=
G-401M1rnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTzWVB4UUN3ME2xMlkzPDJ6IN88US=>NXT2ZYI{W0GQR1XS
SW780NELESnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTFwOU[yOFYh|ryPNEjpXFZUSU6JRWK=
SW872Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFS5d2hKSzVyPUGuPVg{OyEQvF2=MnfmV2FPT0WU
NB7M3XySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYL0XoIxUUN3ME2xMlk6OzJ|IN88US=>MnHNV2FPT0WU
T98GNInwOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXJNGxKSzVyPUKuNFA3PjZizszNMVnTRW5ITVJ?
SW1710M{DIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4mycmlEPTB;Mj6wOlk1PSEQvF2=M3;ndnNCVkeHUh?=
NCI-H1573NXLYUpFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvy[2dUUUN3ME2yMlA4Ojl6IN88US=>MmjVV2FPT0WU
KE-37NWT4b|lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTJwMEi5OVEh|ryPMVLTRW5ITVJ?
786-0NIHlWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;NTIlKSzVyPUKuNVU1OzlizszNNIDnfIVUSU6JRWK=
SASMm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXrGV5pyUUN3ME2yMlIxOzd2IN88US=>MXzTRW5ITVJ?
CAL-54NWLKVnNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTJwMkC0NVMh|ryPMVzTRW5ITVJ?
SF268M2nnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTJwMkOxNlIh|ryPNXfQdpdTW0GQR1XS
SW620M1XIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXvU2FIUUN3ME2yMlI3OTZ7IN88US=>Mnj1V2FPT0WU
MN-60MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTJwM{GwOkDPxE1?MoHqV2FPT0WU
EFO-27NUTibmU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33BbmlEPTB;Mj6zNlA2QCEQvF2=MUXTRW5ITVJ?
NCI-H747MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\OTWM2OD1{LkOyNVk6KM7:TR?=MULTRW5ITVJ?
HCC2218M1TNR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTJwM{WzO|Qh|ryPMn;BV2FPT0WU
MIA-PaCa-2NXr4dW5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTJwM{[0N|ch|ryPNHewfJVUSU6JRWK=
SJSA-1NX;ve2dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7sTWM2OD1{LkO3O|k3KM7:TR?=M{S3[3NCVkeHUh?=
RKOMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3ZbG9KSzVyPUKuN|g1QTZizszNNV7wRpY1W0GQR1XS
NB6NWLKNI1QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWH2dGJ1UUN3ME2yMlQxOzd2IN88US=>NFzEUoJUSU6JRWK=
ES4NXeyXFRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVv5[Io5UUN3ME2yMlQ2PDJ{IN88US=>M4jC[nNCVkeHUh?=
EGI-1M{Ds[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInEUHFKSzVyPUKuOFY5QDNizszNM1vZd3NCVkeHUh?=
CTV-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHJeIJKSzVyPUKuOVI4PzNizszNM3[xNHNCVkeHUh?=
NCI-H1355MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXZdmdSUUN3ME2yMlU2QTVzIN88US=>NGjodVdUSU6JRWK=
GT3TKBMnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHsfJFZUUN3ME2yMlU6OTl7IN88US=>NILNUGFUSU6JRWK=
SK-HEP-1MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfjNXJKSzVyPUKuOVkzPjZizszNM3nNUnNCVkeHUh?=
GAMGM{DMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\hSnpKSzVyPUKuOVk{QTRizszNNXL3Wlh6W0GQR1XS
SK-MES-1NUDSbmdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHmz[2lKSzVyPUKuOlE5ODNizszNMX7TRW5ITVJ?
RO82-W-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTJwNkKwOVch|ryPMXjTRW5ITVJ?
ECC10MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\YboM3UUN3ME2yMlcxOjB4IN88US=>MW\TRW5ITVJ?
MCF7M2Pwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3PTWM2OD1{LkexOFY1KM7:TR?=MXfTRW5ITVJ?
D-283MEDMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTJwN{K0N{DPxE1?NV[0WFdzW0GQR1XS
RPMI-7951NF3WV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYnCRnJzUUN3ME2yMlc2Pjl2IN88US=>MU\TRW5ITVJ?
Ramos-2G6-4C10NGPDOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn34TWM2OD1{Lke3NFk6KM7:TR?=NFvEd4lUSU6JRWK=
KGNMo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTJwOEG4PFQh|ryPNYi1T3B{W0GQR1XS
NUGC-3M3zNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILEdmxKSzVyPUKuPFI2ODVizszNMYnTRW5ITVJ?
NCI-H292NITV[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLjSJM1UUN3ME2yMlg2ODV|IN88US=>Mnf0V2FPT0WU
BeckerMofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HUb2lEPTB;Mj65OVg{OiEQvF2=MlLnV2FPT0WU
NCI-H1299MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTNwMEWyOlMh|ryPMVfTRW5ITVJ?
ETK-1NYSzSmVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\sTWM2OD1|LkC1OFMh|ryPNFy5NI1USU6JRWK=
TK10NWKwNXp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TpW2lEPTB;Mz6yNFE3PSEQvF2=NEe1XJFUSU6JRWK=
VMRC-RCZMnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTMXmZFUUN3ME2zMlM3PDh6IN88US=>NVPWcJZMW0GQR1XS
YH-13NULQfJB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTNwNESwO|kh|ryPMn3GV2FPT0WU
DU-145NW\2Nm5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33RRmlEPTB;Mz60OlI3QSEQvF2=MV;TRW5ITVJ?
SW1088MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrwTWM2OD1|LkS3OFch|ryPM{nhc3NCVkeHUh?=
HOP-92MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHXbpFwUUN3ME2zMlUxOzR{IN88US=>NVHiU3NqW0GQR1XS
KP-N-YSM{[wPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DDd2lEPTB;Mz62NlE{QSEQvF2=NWrtTpB4W0GQR1XS
NCI-H460M2HSUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPITWM2OD1|Lk[2O|Mh|ryPNXHpOWpYW0GQR1XS
U-2-OSNETmbGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTNwN{K1N|Uh|ryPNHL5PFFUSU6JRWK=
A101DMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PST2lEPTB;Mz63Olk{PiEQvF2=NGW3d4tUSU6JRWK=
MDA-MB-231NVj0dnRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTNwOEG5OVEh|ryPNHe1VINUSU6JRWK=
IST-MES1NUnGOmhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTNwOEOyJO69VQ>?MW\TRW5ITVJ?
COR-L105NFiwdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVO0PYFQUUN3ME20MlAyQCEQvF2=MYDTRW5ITVJ?
NCI-H1437NFnyO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfKTWM2OD12LkCyN|AzKM7:TR?=M2rucnNCVkeHUh?=
CAL-85-1MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDQTWM2OD12LkCyOFYyKM7:TR?=M3i2Z3NCVkeHUh?=
MZ1-PCMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zHeGlEPTB;ND6xPFU2PiEQvF2=NGOwW41USU6JRWK=
VM-CUB-1NFjxRmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1TZNWlEPTB;ND6zNVI5PCEQvF2=MVLTRW5ITVJ?
CHL-1NFW5O3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjPXFFKSzVyPUSuN|IyPjlizszNNHjPXJlUSU6JRWK=
MDA-MB-361Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTRwM{OxOVMh|ryPMVzTRW5ITVJ?
NCI-H661NF;TRWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jNW2lEPTB;ND61NFA6OiEQvF2=MnPEV2FPT0WU
EW-11M4\oZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTRwNUKyN|Eh|ryPNWOxXnp2W0GQR1XS
BENMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjuNYxKSzVyPUSuOVI5OTVizszNNGK4VYRUSU6JRWK=
BFTC-909M2XkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTRwNU[yO|Uh|ryPM{XHSnNCVkeHUh?=
NCI-H2087NUXkWVhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHK3SoVKSzVyPUSuOVgyPjRizszNNVT5NXc4W0GQR1XS
RVH-421NWTZOFJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFOzU5RKSzVyPUSuOlY3QSEQvF2=NHvZdWxUSU6JRWK=
P30-OHKNF\3cYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTRwNkiwNFgh|ryPM1fHb3NCVkeHUh?=
NCI-H28MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRTRwOEG2OlEh|ryPNUnq[mFrW0GQR1XS
ES6MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4qw[GlEPTB;ND64N|AyPiEQvF2=NEns[m5USU6JRWK=
769-PNUiwe3ZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDhTWM2OD12Lki1PVI3KM7:TR?=NIPFWJRUSU6JRWK=
OE33MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDYUlNKSzVyPUSuPFgyPjFizszNM3\wc3NCVkeHUh?=
SW982MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;K[ohIUUN3ME20Mlk2ODZzIN88US=>NX;INIdFW0GQR1XS
A388M4TOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHBS3BKSzVyPUWuNFI6QDNizszNM3PHWXNCVkeHUh?=
TI-73MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlH0TWM2OD13LkC2NVk1KM7:TR?=NGPoUVBUSU6JRWK=
HCT-116M4DoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;STWM2OD13LkC5PFg6KM7:TR?=NVTpe4dRW0GQR1XS
HuP-T3Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLnRnRKSzVyPUWuNVg4ODlizszNMWPTRW5ITVJ?
G-402NXrx[mxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTVwMUm0NVYh|ryPNXTOPYNoW0GQR1XS
NCI-H1792M{\Scmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nEUGlEPTB;NT6yOFYzOiEQvF2=M{nPR3NCVkeHUh?=
NCI-H209NEKyUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvuSlhKSzVyPUWuNlU6PDJizszNM{\hOnNCVkeHUh?=
NCI-H1650NFfIPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTVwM{C2N|Qh|ryPM1XFdXNCVkeHUh?=
LCLC-97TM1Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3KwVmlEPTB;NT6zNVgxQCEQvF2=MljaV2FPT0WU
S-117M2DUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnS1TWM2OD13LkO2PVc3KM7:TR?=NFrPXlVUSU6JRWK=
GI-ME-NMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTVwM{m2PFEh|ryPMYrTRW5ITVJ?
NCI-H2122MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLsTWM2OD13LkS5N|k4KM7:TR?=MYnTRW5ITVJ?
NCI-H1793M{nmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjKVm9KSzVyPUWuOlc2QTNizszNMY\TRW5ITVJ?
C2BBe1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTVwN{CwPFgh|ryPMnv5V2FPT0WU
TE-12NWG1dYs4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTVwOEC1OVYh|ryPNEXQ[2ZUSU6JRWK=
LCLC-103HNFvFe|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTVwOUG3JO69VQ>?NYjWTY9FW0GQR1XS
A673NU[zVnB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jsZmlEPTB;NT65NVk{OiEQvF2=M1W0XHNCVkeHUh?=
BB30-HNCNWOxZWh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzlbJZOUUN3ME21Mlk5OzZizszNMXPTRW5ITVJ?
SF295MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXviVIY2UUN3ME22MlAxPDJ{IN88US=>MXvTRW5ITVJ?
KU-19-19NEfXelNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XHOGlEPTB;Nj6wNVc{OSEQvF2=M{PqZ3NCVkeHUh?=
CFPAC-1MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zxOmlEPTB;Nj6wOFQ1OyEQvF2=Ml\CV2FPT0WU
LoVoM3KwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTZwMEWwOlMh|ryPNGrO[FJUSU6JRWK=
8505CMkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGG5dm9KSzVyPU[uNFc2PzNizszNMYXTRW5ITVJ?
GMS-10M2G5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEm1SppKSzVyPU[uNVUxODJizszNNILOSnZUSU6JRWK=
Ca9-22MmH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTpVWUzUUN3ME22MlE3PzFizszNNIDHXoJUSU6JRWK=
DOKMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDrTWM2OD14LkKyNFczKM7:TR?=M{HhUHNCVkeHUh?=
FADUMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTZwMk[wN|kh|ryPNFOze3RUSU6JRWK=
BxPC-3M3LlWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfRe3FsUUN3ME22MlI4OzJizszNMnHkV2FPT0WU
CAL-33NUTwSHpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTZwMkmyNFEh|ryPMoj3V2FPT0WU
SHP-77NUTOe4x3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HPXmlEPTB;Nj6zNVUyOiEQvF2=NEjLN4tUSU6JRWK=
LXF-289MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MknHTWM2OD14LkOzOFU2KM7:TR?=MYHTRW5ITVJ?
GB-1MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mne4TWM2OD14LkO4NkDPxE1?MmDsV2FPT0WU
KS-1Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTyXZlJUUN3ME22MlM5PDR5IN88US=>M3PU[nNCVkeHUh?=
D-502MGNH\Fc3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXSTWM2OD14LkSyN|c3KM7:TR?=MojlV2FPT0WU
LAN-6M2LSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\QeGlEPTB;Nj61NVAzOyEQvF2=NU\yVog1W0GQR1XS
H-EMC-SSMoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTZwNU[xOFch|ryPNY\ScJlnW0GQR1XS
LC-2-adMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHo[pJxUUN3ME22MlYxODd4IN88US=>MYnTRW5ITVJ?
NCI-H1693M3LH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjrRnh4UUN3ME22MlYzOjF3IN88US=>NILxcY1USU6JRWK=
SK-N-FIMlvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TDS2lEPTB;Nj63OVA1PCEQvF2=MnviV2FPT0WU
D-423MGNITWbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGjzV49KSzVyPU[uO|YyOTdizszNMWTTRW5ITVJ?
KNS-42NXLI[493T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzjTWM2OD14Lke4NVk4KM7:TR?=NXn0S|FOW0GQR1XS
GCTNEfEZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3wTWM2OD14LkmzPEDPxE1?NGmxbHFUSU6JRWK=
DSH1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVnEfWdSUUN3ME23MlA3OzNizszNNUDGcIVnW0GQR1XS
D-247MGMmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXmXphKSzVyPUeuNFc5QDFizszNNXi3U4xMW0GQR1XS
NCI-SNU-5NHPXcGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTdwMUizO|Eh|ryPMYfTRW5ITVJ?
TE-6M1PnPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1L1U2lEPTB;Nz6yNFYxOSEQvF2=NEDwRnFUSU6JRWK=
NOMO-1NHjtXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTdwMkKxNlch|ryPMXnTRW5ITVJ?
NB17NFjzUVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTdwM{CzNFkh|ryPMlS0V2FPT0WU
EW-22NXrNVZBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7FSYJKSzVyPUeuN|Q{PDhizszNM4TkcnNCVkeHUh?=
EW-13M1vZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;yZVJCUUN3ME23MlM2OTZ{IN88US=>NVKwZ3FFW0GQR1XS
DOHH-2M2Xj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjWfoh6UUN3ME23MlQ1ODJizszNM1vWRnNCVkeHUh?=
TGBC1TKBM2rpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTdwNEm4PVkh|ryPMYXTRW5ITVJ?
GR-STNHn5NHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWX0eZNIUUN3ME23MlUzPTl2IN88US=>MYLTRW5ITVJ?
KYSE-520M3jwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jiOGlEPTB;Nz61OVUyPSEQvF2=Mn36V2FPT0WU
CAPAN-1NVjSSFNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTWTWM2OD15LkW5OVEh|ryPMlzkV2FPT0WU
HCE-4NYHDbIhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTdwNkKyO|kh|ryPMnTxV2FPT0WU
MLMAMofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\vTWM2OD15Lk[yPVU4KM7:TR?=M{C2ZnNCVkeHUh?=
HT-144NYjzZm1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfFZ3kxUUN3ME23MlY2OzZ6IN88US=>MXnTRW5ITVJ?
KYSE-180M2fTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13sXmlEPTB;Nz63NVE3QSEQvF2=MYrTRW5ITVJ?
TE-5MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nvNWlEPTB;Nz65OVk4OSEQvF2=M3rncXNCVkeHUh?=
IGROV-1M4[zVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTdwOUi1OVEh|ryPM3\reXNCVkeHUh?=
NCI-H1581MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRThwMEGyJO69VQ>?NEPwNnZUSU6JRWK=
SW1990NHu4OpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXNTWM2OD16LkC0OlU6KM7:TR?=M{XZSXNCVkeHUh?=
EFM-19M{PlOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmD4TWM2OD16LkC4OVQ2KM7:TR?=MYHTRW5ITVJ?
OGR-1MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TxSmlEPTB;OD60N|AzOyEQvF2=MUjTRW5ITVJ?
U-118-MGMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTSO5ZMUUN3ME24MlQ{PDZ|IN88US=>MnizV2FPT0WU
SK-OV-3M{D3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV:xUVdXUUN3ME24MlQ3PzZ3IN88US=>MkDBV2FPT0WU
KNS-62NV7SSVBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVP1ZoJYUUN3ME24MlUyPzZzIN88US=>MWTTRW5ITVJ?
GOTOMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRThwNUe2N|Uh|ryPMoPLV2FPT0WU
8305CMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljhTWM2OD16LkewOFg1KM7:TR?=M3HneHNCVkeHUh?=
RPMI-2650NGPnO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnvyTWM2OD16LkexPVU2KM7:TR?=NFfhW|RUSU6JRWK=
NEC8NGmxNJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrFT4RKSzVyPUiuO|Q{ODdizszNNXTodm4zW0GQR1XS
KYSE-450NUDHZWtiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXLTWM2OD16Lki2OVQ5KM7:TR?=NFzlc2dUSU6JRWK=
RMG-INH\QPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUmwXnFqUUN3ME25MlE1ODV6IN88US=>NUS5PWhRW0GQR1XS
CAKI-1MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XTVGlEPTB;OT6zNVk4QSEQvF2=NXqxXXNuW0GQR1XS
KYSE-510MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTlwM{W3O|gh|ryPNUfxSHhrW0GQR1XS
A4-FukMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3r0c2lEPTB;OT6zOlcxOSEQvF2=NFfMNpZUSU6JRWK=
AN3-CAMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTlwNEW0OFQh|ryPMnqwV2FPT0WU
SK-N-DZMn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLVVlVKSzVyPUmuO|I5PDlizszNNIDv[mpUSU6JRWK=
HSC-2NX3RcWhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3uxZmlEPTB;OT63OlYzQSEQvF2=NELlRVNUSU6JRWK=
EW-1MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3RUmlXUUN3ME25Mlc6OzZ7IN88US=>NIPtWYRUSU6JRWK=
D-566MGMl3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTlwOEO2OlQh|ryPNX:3dJVLW0GQR1XS
COLO-792M1TaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLtXlY2UUN3ME25Mlk5PzR4IN88US=>NX;UbngzW0GQR1XS
TE-10M4nZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHe3XYpKSzVyPUGwMlA{QTZizszNM2PRbnNCVkeHUh?=
NCI-H650MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrUSIpKSzVyPUGwMlQzQDZizszNMn7iV2FPT0WU
U-266NXfCOFhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjUVnFrUUN3ME2xNE41PTVizszNMVvTRW5ITVJ?
Detroit562M3L1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVf2NI5tUUN3ME2xNU4xPTF3IN88US=>MkXuV2FPT0WU
NH-12NH3aV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLXeIZCUUN3ME2xNU4yPDR4IN88US=>M{TGcnNCVkeHUh?=
CO-314MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLKTWM2OD1zMT6yPFQzKM7:TR?=NU\QfW1XW0GQR1XS
IST-MEL1MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIntNFZKSzVyPUGxMlU{OjNizszNM2fFN3NCVkeHUh?=
KNS-81-FDNXPXTIN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTFzLkW1Nlch|ryPM1G1cXNCVkeHUh?=
SW1463MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofWTWM2OD1zMT61PVg6KM7:TR?=Moi3V2FPT0WU
NCI-H23NED5ZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTFzLk[1OVIh|ryPM3nPVnNCVkeHUh?=
SK-MEL-2MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTFzLkexPVch|ryPMkHPV2FPT0WU
NB13NG\TToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTF{LkG0PVUh|ryPNX7ac2tiW0GQR1XS
DaoyNG\WSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\zc2lEPTB;MUKuNlg2PiEQvF2=MnvlV2FPT0WU
NCI-H1623M4D6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTF{LkO4NFEh|ryPMoSyV2FPT0WU
NMC-G1NH6wUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\ycmlEPTB;MUKuO|E4KM7:TR?=NWjzVG1pW0GQR1XS
DK-MGNGflWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vxVmlEPTB;MUKuPVQ5OiEQvF2=MlHDV2FPT0WU
TCCSUPNGjvVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTF|LkGyPFQh|ryPNYP5UlRTW0GQR1XS
SCC-15MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWH5dlcyUUN3ME2xN{4zPjVzIN88US=>M{LqUXNCVkeHUh?=
NOS-1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHybY5KSzVyPUGzMlI5QTNizszNMYnTRW5ITVJ?
RH-1MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUX5OZVWUUN3ME2xN{4{ODN5IN88US=>MXLTRW5ITVJ?
SK-MEL-3MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHT3dHhKSzVyPUGzMlM4OjhizszNNYW4T2FmW0GQR1XS
NB5NFX1dFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTF|LkSwOlch|ryPM2XDN3NCVkeHUh?=
SNU-387M3jFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGXuTY5KSzVyPUGzMlUxPzJizszNNHvSfZdUSU6JRWK=
CAL-120M4rnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjZ[pVGUUN3ME2xN{43PzF6IN88US=>MXPTRW5ITVJ?
Mo-TM{P2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlu1TWM2OD1zMz63NFch|ryPNHXRcXlUSU6JRWK=
LNCaP-Clone-FGCNGTyOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NISyWnJKSzVyPUGzMlc6QTJizszNNVjqeIJKW0GQR1XS
CANM3n1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTF2LkCyPFgh|ryPM1TnXnNCVkeHUh?=
SK-MEL-30NVPldIlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;xXYNKSzVyPUG0MlA3OyEQvF2=NYq0Wo46W0GQR1XS
COLO-678M1fsOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHv4O|hKSzVyPUG0MlA5OjJizszNMmHIV2FPT0WU
SCC-9NWHUNpJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWK3fXR3UUN3ME2xOE4yODJzIN88US=>M4LWWXNCVkeHUh?=
KINGS-1NYH4OYFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHEboh1UUN3ME2xOE4yPDB{IN88US=>NFPrUoxUSU6JRWK=
SL-513MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1f0TmlEPTB;MUSuNVg4KM7:TR?=NV:4Z|FwW0GQR1XS
HLEM3;yNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmL3TWM2OD1zND6zPFUzKM7:TR?=NIHP[YZUSU6JRWK=
SW1573MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\EdZc5UUN3ME2xOE41PDN3IN88US=>MYTTRW5ITVJ?
KYSE-140NHfGfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTF2Lk[zNlch|ryPM2nyWHNCVkeHUh?=
SK-PN-DWMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3se4NKSzVyPUG0MlgxODFizszNMWXTRW5ITVJ?
A253M{XsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPrTWM2OD1zNT6wOlI2KM7:TR?=MlzyV2FPT0WU
CAL-12TNXKwcoJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\IWmdNUUN3ME2xOU41PjZ{IN88US=>MkHvV2FPT0WU
COLO-679MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTF3Lke2PFMh|ryPMnfZV2FPT0WU
UACC-257M4H5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vodWlEPTB;MU[uNVIxOSEQvF2=MlHhV2FPT0WU
U-87-MGMnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXiTndKSzVyPUG2MlM2OjNizszNMUjTRW5ITVJ?
HCC1806MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTF4LkewO|Eh|ryPNFLudWVUSU6JRWK=
NCI-H2170NHLsepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTF5LkK0OFgh|ryPMVnTRW5ITVJ?
AGSNHvoU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXTtW3UxUUN3ME2xO{4{QDB6IN88US=>M1TKWXNCVkeHUh?=
MEL-HOMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXFTWM2OD1zNz63OVA{KM7:TR?=NVjLN49IW0GQR1XS
SW48MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;WeZJKSzVyPUG3Mlc4OTZizszNMl;VV2FPT0WU
HuP-T4NELV[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYT0fGtLUUN3ME2xPE4xOjB4IN88US=>M2fjNHNCVkeHUh?=
NCI-H720NWfablNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmO3TWM2OD1zOD6xOFAzKM7:TR?=NVXHfGlFW0GQR1XS
RCC10RGBNGPNdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfJPGI4UUN3ME2xPE4yPjl5IN88US=>Mmj2V2FPT0WU
HD-MY-ZNGDzWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFn0bYdKSzVyPUG4MlIzPTRizszNMUnTRW5ITVJ?
A427MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTF6LkWwPVQh|ryPM4Hx[3NCVkeHUh?=
HCC2998Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUP1e3dDUUN3ME2xPE43ODVzIN88US=>MWfTRW5ITVJ?
EPLC-272HNIH5c2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2j1c2lEPTB;MUmuNFQ{PCEQvF2=MnPTV2FPT0WU
C32M33LZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2DOcWlEPTB;MUmuNFQ2KM7:TR?=M{LEeXNCVkeHUh?=
UMC-11Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDyXlhKSzVyPUG5MlIyOjNizszNNV3JOYVHW0GQR1XS
CaR-1NXnKfWRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1[yZWlEPTB;MUmuOlgxPCEQvF2=M3vXTXNCVkeHUh?=
KYSE-410NEL2[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTF7LkmxN|kh|ryPNEXMTnVUSU6JRWK=
HuCCT1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFKw[oFKSzVyPUKwMlYzQTRizszNM{HSbXNCVkeHUh?=
LB996-RCCMlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPmNJpKSzVyPUKwMlcyPjhizszNMVTTRW5ITVJ?
KYSE-70NETucIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2Lwb2lEPTB;MkCuPFA2QSEQvF2=NHXzeldUSU6JRWK=
CAL-72MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnOzTWM2OD1{MD65NVUh|ryPM{fH[3NCVkeHUh?=
Capan-2NXztfGhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{CyOmlEPTB;MkGuNFQyOyEQvF2=Mlr1V2FPT0WU
PANC-08-13Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PFWmlEPTB;MkGuNlUyPSEQvF2=NYjHTphvW0GQR1XS
SBC-1NXjZRnhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHXOcoRKSzVyPUKxMlMxQDFizszNMUDTRW5ITVJ?
MFM-223NV65Uo04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEC3[nNKSzVyPUKxMlM{PDJizszNMVrTRW5ITVJ?
BB49-HNCNX;MeZZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWX1UHVMUUN3ME2yNU42PzF4IN88US=>NGTDUW5USU6JRWK=
SH-4NH\IZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTJzLk[2NVgh|ryPMnjMV2FPT0WU
HuO9MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLBTWM2OD1{MT65PFI2KM7:TR?=MXHTRW5ITVJ?
AM-38M1HIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHTTe4VKSzVyPUKyMlA1QDVizszNMnLxV2FPT0WU
A431NHzJNllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHrUXhkUUN3ME2yN{4zOTF7IN88US=>NF[xR4pUSU6JRWK=
YAPCNVj2cFdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXG4Wm8{UUN3ME2yN{4zPjVzIN88US=>NU\Hfoc6W0GQR1XS
LU-139MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUniWoI6UUN3ME2yN{41QDB7IN88US=>Ml2wV2FPT0WU
HEC-1MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M374OGlEPTB;MkOuOFk{PyEQvF2=NHrVbVFUSU6JRWK=
SCC-25NI\afZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPEbmkxUUN3ME2yOE4{ODB4IN88US=>MWrTRW5ITVJ?
HT-29MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTJ2LkO4NlMh|ryPMnn4V2FPT0WU
PC-14M17LOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTJ2Lk[1O|Eh|ryPMom4V2FPT0WU
Calu-6NWeySYNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;VTWM2OD1{NT61NFcyKM7:TR?=NF34NI9USU6JRWK=
SJRH30M1K4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\5TGMxUUN3ME2yOU43PDl4IN88US=>MWfTRW5ITVJ?
ChaGo-K-1NXv2VIxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XqPGlEPTB;Mk[uNVYzQSEQvF2=MkHoV2FPT0WU
IA-LMMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jBTWlEPTB;Mk[uN|Y1PSEQvF2=NHu2TYpUSU6JRWK=
GP5dNWD4R3d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTJ4LkS0PVEh|ryPMV7TRW5ITVJ?
NCI-H2291M3ftOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfUTYNKSzVyPUK2MlY2PDFizszNM3HPPXNCVkeHUh?=
BALL-1M3Li[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvvNoliUUN3ME2yOk46Ozl5IN88US=>NUn2[XI{W0GQR1XS
HCC1954M1rZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnJTWM2OD1{Nj65PFA5KM7:TR?=M2PFcHNCVkeHUh?=
NCI-H2452M{DnPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTLTWM2OD1{Nz60NVY{KM7:TR?=Mn21V2FPT0WU
LU-99AMnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfxN|dKSzVyPUK3MlU2QDJizszNM2\YNXNCVkeHUh?=
NTERA-S-cl-D1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TvO2lEPTB;MkeuO|I6QSEQvF2=MVHTRW5ITVJ?
PANC-10-05MknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DBemlEPTB;MkeuO|c4PSEQvF2=NVXKdoFsW0GQR1XS
NCI-H2405NGntS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPjTWM2OD1{Nz65N|g4KM7:TR?=MV\TRW5ITVJ?
MDA-MB-415NFP1UotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkG5TWM2OD1{OD60NVM4KM7:TR?=NFHUOmxUSU6JRWK=
NCI-H2342M2HCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlviTWM2OD1{OD61NlgyKM7:TR?=Mn;DV2FPT0WU
TGBC24TKBNYLTNY9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3[4c2lEPTB;MkiuO|EyPyEQvF2=NYHoU2MxW0GQR1XS
LU-134-ANWfRWG5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfhbGp6UUN3ME2yPE46OjZzIN88US=>NH23dG1USU6JRWK=
SCC-4NVPzbW91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTNzLkC0PVQh|ryPMX\TRW5ITVJ?
Saos-2NUDEOFNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1m3N2lEPTB;M{GuPVMxPiEQvF2=M2nPOHNCVkeHUh?=
RERF-LC-MSNYXLd2oxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTN{LkiyN|Eh|ryPMmDmV2FPT0WU
M14MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTN{Lkm3OlQh|ryPMUPTRW5ITVJ?
HPAF-IINXvtVHlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HG[WlEPTB;M{OuOVAyOSEQvF2=NGfONo5USU6JRWK=
NCI-H1755M2nB[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mne2TWM2OD1|ND6zN|A2KM7:TR?=MXjTRW5ITVJ?
D-392MGMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfNcItqUUN3ME2zOU45Pjd2IN88US=>NF:2[FlUSU6JRWK=
A704MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3rZZdKSzVyPUO2MlA1OjdizszNM3\qO3NCVkeHUh?=
CP50-MEL-BNFi2SolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3jTWM2OD1|Nj6xPVEyKM7:TR?=MnXRV2FPT0WU
EW-18NIPjZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fnZ2lEPTB;M{[uOFUzKM7:TR?=NUOyXYtHW0GQR1XS
WM-115NYK2W5l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rkVGlEPTB;M{[uPFA6QSEQvF2=MXnTRW5ITVJ?
LU-65MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTN5LkG0NVch|ryPNX:3cW9LW0GQR1XS
NCI-H1563M1;YXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITqNnNKSzVyPUO3MlI1QDRizszNNX\hdIJpW0GQR1XS
DBTRG-05MGMkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITGTVFKSzVyPUO4MlA3QTFizszNM4f3bXNCVkeHUh?=
NCI-H630NFvQT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVnDeW9ZUUN3ME2zPE41PzF2IN88US=>NIOzbYNUSU6JRWK=
NCI-H1155NYDNdmdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPJUXhrUUN3ME2zPU4zPDJizszNNVrhZY5GW0GQR1XS
OVACR-3NWXzWYFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTN7LkmxPVUh|ryPNHvEd5NUSU6JRWK=
OAW-42M4TxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTRyLkSyOVgh|ryPMonBV2FPT0WU
JVM-2NXe0ZZA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHT4RVlKSzVyPUSxMlI1OTVizszNMW\TRW5ITVJ?
C3ANHHve2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1W2U2lEPTB;NEGuN|Q1PyEQvF2=M{L2ZXNCVkeHUh?=
HT55NV;GdGNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTR{LkK4OFEh|ryPMnv0V2FPT0WU
OVCAR-4M1XtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTR{LkK5O|Qh|ryPNGXTTJlUSU6JRWK=
MEG-01MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\IZ4pNUUN3ME20Nk41PjF4IN88US=>NVrqfW84W0GQR1XS
NCI-H82MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTR|Lkm4PVIh|ryPNGXob2RUSU6JRWK=
JEG-3NV3WeY43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTR2Lkm0O{DPxE1?NYCxOZZlW0GQR1XS
BPH-1NVLQ[I5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTR4LkO5PVgh|ryPNG\VW49USU6JRWK=
MPP-89Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTR5LkK4PVgh|ryPNITiOVNUSU6JRWK=
ALL-PONFPNdW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\LTWM2OD12Nz60NVg5KM7:TR?=MYjTRW5ITVJ?
HTNF7IUGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPkdlBKSzVyPUS3MlQ6OiEQvF2=MmDGV2FPT0WU
NCI-H2347Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVX2OlNCUUN3ME20PE4xPzF3IN88US=>NHz3TXBUSU6JRWK=
A2780Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jPO2lEPTB;NEmuOFIzQCEQvF2=NIDtdVNUSU6JRWK=
KARPAS-299MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnT1TWM2OD12OT61NVE6KM7:TR?=MV\TRW5ITVJ?
NCI-H1651NGDRTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLweHBJUUN3ME20PU45QDJzIN88US=>NGHFOZVUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

Protocol(Only for Reference)

Kinase Assay: [1]

Cdk Assays A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.

Cell Assay: [1]

Cell lines Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
Concentrations 0.01-1 μM
Incubation Time 24 hours
Method Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.

Animal Study: [1]

Animal Models Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
Formulation Dissolved in sodium lactate buffer (50 mM, pH 4.0)
Dosages 0-150 mg/kg
Administration Given by gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Fry DW, et al. Mol Cancer Ther, 2004, 3(11), 1427-1438.

[2] Menu E, et al. Cancer Res, 2008, 68(14), 5519-5523.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-04-16)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02730429 Not yet recruiting Endometrial Cancer Nordic Society for Gynaecologic Oncology|ENGOT|GCIG August 2016 Phase 2
NCT02738866 Not yet recruiting Metastatic Breast Cancer Sidney Kimmel Comprehensive Cancer Center|Pfizer July 2016 Phase 2
NCT02684032 Not yet recruiting Breast Cancer Pfizer May 2016 Phase 1
NCT02600923 Not yet recruiting Advanced Breast Cancer (Female) Pfizer April 2016 Phase 3
NCT02668666 Not yet recruiting Hormone Receptor Positive Malignant Neoplasm of Breast|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Estrogen Receptor Positive Brea  ...more Hormone Receptor Positive Malignant Neoplasm of Breast|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Estrogen Receptor Positive Breast Cancer|Progesterone Receptor Positive Tumor|Metastatic Breast Cancer Oana Danciu, MD|Pfizer|Hoosier Cancer Research Network|Bi  ...more Oana Danciu, MD|Pfizer|Hoosier Cancer Research Network|Big Ten Cancer Research Consortium March 2016 Phase 2

view more

Chemical Information

Download Palbociclib (PD-0332991) HCl SDF
Molecular Weight (MW) 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 3 mg/mL warmed (6.19 mM)
Water 30 mg/mL (61.98 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo Saline 20 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 6-acetyl-8-cyclopentyl-5-methyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride

Customer Product Validation (6)


Click to enlarge
Rating
Source Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck
Method Western Blot/Growth assay
Cell Lines OE33/OE19/Flo1A cells
Concentrations 125 nM
Incubation Time 1/3/21 day
Results PD-0332991 reduces expression of cyclinA in all 3 cell lines. PD-0332991 has no effect on the expression level of either total pRB or RB2 (p130) in EAC cells. PD-0332991 caused a significant reduction in colony formation in soft agar in all 3 cell lines tested, indicative of a reduction in anchorage independence.

Click to enlarge
Rating
Source Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck
Method Immunofluorescence
Cell Lines Patient tumor cell
Concentrations 3 uM
Incubation Time
Results Tumor organoids treated with VPA/ PD0332991 or SAHA/PD0332991 exhibited reduced structural integrity and increased cellular scatter with increasing concentrations of the drugs.

Click to enlarge
Rating
Source Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck
Method Immunofluorescence
Cell Lines Murine MSCs cells
Concentrations 2 uM
Incubation Time 24-48 h
Results We show that when cells are treated with PD332991 for 24–48 h there is a marked decrease in nuclear expression of cdk4 in PAX7- FKHR-expressing mMSCs. Further analysis by immunofluorescence showed that there is a minor upregulation in expression of MyoD1 in cells treated with cdk4 inhibitor for 48 h.

Click to enlarge
Rating
Source Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck
Method Western blot
Cell Lines WM3734 melanoma cells
Concentrations 0.25-4 μM
Incubation Time 36 h
Results

Click to enlarge
Rating
Source Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck
Method Western blot
Cell Lines T98G glioma cells
Concentrations 1 μM
Incubation Time
Results

Click to enlarge
Rating
Source Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck
Method IB analysis, Quantification of soft agar assays
Cell Lines LN319 cells
Concentrations
Incubation Time
Results

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related CDK Products

  • SU9516

    SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.

  • Ro-3306

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • Purvalanol A

    Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.

  • Palbociclib (PD0332991) Isethionate

    Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

    Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.

  • Dinaciclib (SCH727965)

    Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.

  • Flavopiridol (Alvocidib) HCl

    Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.

  • Roscovitine (Seliciclib,CYC202)

    Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.

  • LY2835219

    LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.

  • Ribociclib (LEE011)

    Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

  • SNS-032 (BMS-387032)

    SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.

Recently Viewed Items

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us